SSGJ-707 in Advanced Non-Small Cell Lung Cancer

This study is testing a new drug called SSGJ-707 in people with advanced non-small cell lung cancer (NSCLC) who have not yet received systemic treatment. SSGJ-707 is a bispecific antibody — it targets two proteins at once (PD-1 and VEGF) to help the immune system attack cancer while also cutting off its blood supply. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of locally advanced or metastatic (stage IIIB–IV) NSCLC - You have not yet received any systemic treatment for your advanced lung cancer - You are in good physical condition (able to care for yourself and perform daily activities) - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - Your lung cancer has a specific genetic mutation (such as EGFR, ALK, BRAF, MET, NTRK, RET, or ROS1) - Your cancer includes small cell components - You have active brain, spinal cord, or leptomeningeal metastases - You have HIV, active tuberculosis, or history of organ/stem cell transplant - You have unresolved side effects from prior treatments Talk to your doctor to see if this trial is right for you.